In a first-in-human phase 1/2 study, GT005, an AAV2-based one-time investigational gene therapy, showed potential to regulate the complement pathway involved in the pathogenesis of geographic ...

Activation of the alternative pathway of the complement system has been implicated in the pathogenesis of age-related macular degeneration. Membrane attack complex (MAC) has been identified mainly ...

A genetic deficiency of factor B confirms the role of the protein in the activation of the alternative complement pathway in humans and in protection against infection by encapsulated bacteria.

To investigate levels of components of the alternative pathway of complement, and of two activation products, ASP and Bb, in persons ranging in insulin resistance both fasting and following the ...

Iptacopan is an innovative, first-in-class oral small molecule that reversibly inhibits factor B—a crucial serine protease in the alternative pathway of the complement system. By targeting this ...

“ARO-CFB also demonstrated dramatic reductions in measures of alternative complement pathway activation, with mean reductions at or approaching 100% in AH50 and Wieslab AP at multiple dose levels.

After a slow start, the race is on to inhibit key proteins and pathways within the complement system -- a biological cascade that is central to the innate immune system and many different diseases ...

In this article, ACROBiosystems discusses how the complement cascade and it's various components could potentially be leveraged for therapeutic potential in COVID-19, cancer and general inflammation.

Disruption of the complement system appears to precede the onset of islet autoimmunity (IA), making it a potential early warning sign of type 1 diabetes (T1D), according to a new report. The ...

Thereby, the modification of C5 Complement pathway for identifying and developing inhibitors is believed to be emerging as a novel targeted therapeutic class for the cancer patients.

Researchers have pinpointed a brain protein that could offer a fresh target in the battle against Alzheimer's.

Researchers identified an interleukin 6 dependent alternative pathway as a therapeutic strategy against coronavirus disease 2019.